Concord Biotech acquires 100% in Celliimune Biotech for ₹66 lakh

Listed Co AcquisitionStrategic Transactions View source PDF

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.7%1-day move

₹1025.00

prior close

₹1010.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.1+0.7+0.3+0.9+0.7+2.4+3.4+3.5+2.4+1.4+5.8+19.2+16.5+25.1

Up moveDown movePending

AI summary

Concord Biotech has acquired 100% stake in Celliimune Biotech Private Limited for ₹66 lakh in cash, completed on April 2, 2026. Celliimune is a biopharma startup (incorporated Jan 2025, nil turnover) focused on DNA engineering for cancer therapeutics and novel cell & gene therapy. The deal is a related party transaction as the promoter group previously held a majority stake in Celliimune; done at arm's length. This follows Concord's earlier intimation dated November 13, 2025.

Likely market impact

Small strategic move into cancer therapy R&D; related-party deal with promoter-linked entity; financial impact minimal given ₹66L size and target's zero revenue.